All In Biotech

Drug Trial Radar · NCT06019728

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Nov 10, 2023

Primary completion

Oct 25, 2024

Study completion Oct 25, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.

Conditions

  • Fabry's Disease

Interventions

  • AGALSIDASE BETA (GZ419828)Drug

    Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion

  • AcetaminophenDrug

    Tablet or solution; Oral

  • DiphenhydramineDrug

    Tablet or solution; Oral

  • DexamethasoneDrug

    Tablet or solution; Oral

  • MontelukastDrug

    Tablet or chewable tablet or oral granules; Oral

  • LoratadineDrug

    Tablet or chewable tablet; Oral

  • CetirizineDrug

    Tablet or oral solution; Oral

  • FexofenadineDrug

    Tablet or oral suspension; Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 InfusionsTime frame: Up to 16 weeks
  2. Shortest Actual Tolerated Infusion DurationTime frame: Up to 16 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center Site Number : 1003

    Santa Monica, California

  • Emory University School of Medicine Site Number : 1005

    Atlanta, Georgia

  • Infusion Associates Site Number : 1001

    Grand Rapids, Michigan

  • Metropolitan Hospital Center Site Number : 1004

    New York, New York

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.